Acasti Pharma Inc GTX-101 and GTX-102 Call Transcript
Good day, and welcome to the Acasti Pharma Business Update Conference Call. All participant will be in on listen-only mode. (Operator Instructions) Please note the event is being recorded. I would now like to turn the conference over to Robert Blum with Lytham Partners.
All right. Thank you very much, [Vishnavi]. As the operator indicated, welcome to Acasti Pharma's Business Update Conference Call to discuss recent preliminary top line results for 2 of the company's drug candidates, which have each met all of their primary outcome measures.
On the call with us this afternoon is Jan D'Alvise, President and CEO and Monique Champagne, VP of Clinical Affairs; [Dr. Dan Sesh], Acasti's Acting Chief Medical Officer; and Brian Ford, Chief Financial Officer. Following management's prepared remarks, there will be a Q&A session. Should any questions remain after the call, please feel free to contact me at 602889-9700. I'd also like to remind everyone that statements on this conference call that are not
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |